Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.

Myasthenia gravis is a paralytic disorder with autoantibodies against acetylcholine receptors at the neuromuscular junction. A proportion of patients instead has antibodies against muscle-specific kinase, a protein essential for acetylcholine receptor clustering. These are generally of the immunoglobulin-G4 subclass and correlate with disease severity, suggesting specific myasthenogenic activity. However, immunoglobulin-G4 subclass antibodies are generally considered to be 'benign' and direct proof for their pathogenicity in muscle-specific kinase myasthenia gravis (or other immunoglobulin-G4-associated disorders) is lacking. Furthermore, the exact electrophysiological synaptic defects caused at neuromuscular junctions by human anti-muscle-specific kinase autoantibodies are hitherto unknown. We show that purified immunoglobulin-G4, but not immunoglobulin-G1-3, from patients with muscle-specific kinase myasthenia gravis binds to mouse neuromuscular junctions in vitro, and that injection into immunodeficient mice causes paralysis. Injected immunoglobulin-G4 caused reduced density and fragmented area of neuromuscular junction acetylcholine receptors. Detailed electrophysiological synaptic analyses revealed severe reduction of postsynaptic acetylcholine sensitivity, and exaggerated depression of presynaptic acetylcholine release during high-rate activity, together causing the (fatigable) muscle weakness. Intriguingly, compensatory transmitter release upregulation, which is the normal homeostatic response in acetylcholine receptor myasthenia gravis, was absent. This conveys extra vulnerability to neurotransmission at muscle-specific kinase myasthenia gravis neuromuscular junctions. Thus, we demonstrate that patient anti-muscle-specific kinase immunoglobulin-G4 is myasthenogenic, independent of additional immune system components, and have elucidated the underlying electrophysiological neuromuscular junction abnormalities.

[1]  W. W. Hofmann,et al.  An electrophysiological investigation of neuro‐muscular transmission in myasthenia gravis , 1964, The Journal of physiology.

[2]  A. Engel,et al.  HISTOMETRIC ANALYSIS OF THE ULTRASTRUCTURE OF THE NEUROMUSCULAR JUNCTION IN MY ASTHENIA GRAVIS AND IN THE MYASTHENIC SYNDROME * , 1971, Annals of the New York Academy of Sciences.

[3]  K L Magleby,et al.  A quantitative description of end‐plate currents , 1972, The Journal of physiology.

[4]  A. Engel,et al.  Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. , 1977, Mayo Clinic proceedings.

[5]  J. Harris,et al.  The relationship between end‐plate size and transmitter release in normal and dystrophic muscles of the mouse. , 1979, The Journal of physiology.

[6]  R. Miledi,et al.  On the release of transmitter at normal, myasthenia gravis and myasthenic syndrome affected human end‐plates. , 1980, The Journal of physiology.

[7]  A. R. Martin,et al.  Non‐linear summation of end‐plate potentials in the frog and mouse. , 1981, The Journal of physiology.

[8]  A. Vincent,et al.  Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles. , 1982, Clinical and experimental immunology.

[9]  J. Fiekers Interactions of edrophonium, physostigmine and methanesulfonyl fluoride with the snake end-plate acetylcholine receptor-channel complex. , 1985, The Journal of pharmacology and experimental therapeutics.

[10]  M. Neuberger,et al.  Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies , 1987, The Journal of experimental medicine.

[11]  S. Nagataki,et al.  Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end‐plate in minimal myasthenia gravis , 1989, Neurology.

[12]  R. Balderas,et al.  The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem). , 1989, The New England journal of medicine.

[13]  J. Plomp,et al.  Adaptation of quantal content to decreased postsynaptic sensitivity at single endplates in alpha‐bungarotoxin‐treated rats. , 1992, The Journal of physiology.

[14]  R. Maselli,et al.  Analysis of anticholinesterase‐induced neuromuscular transmission failure , 1993, Muscle & nerve.

[15]  K. Campbell,et al.  Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoprotein complex , 1995, Neuron.

[16]  P. Distefano,et al.  Receptor tyrosine kinase specific for the skeletal muscle lineage: Expression in embryonic muscle, at the neuromuscular junction, and after injury , 1995, Neuron.

[17]  D. Greiner,et al.  Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. , 1995, Journal of immunology.

[18]  P. Molenaar,et al.  Acetylcholine release in myasthenia gravis: Regulation at single end‐plate level , 1995, Annals of neurology.

[19]  J. Sanes,et al.  Aberrant differentiation of neuromuscular junctions in mice lacking s-laminin/laminin β2 , 1995, Nature.

[20]  S. J. Wood,et al.  The contribution of postsynaptic folds to the safety factor for neuromuscular transmission in rat fast‐ and slow‐twitch muscles. , 1997, The Journal of physiology.

[21]  G. Fischbach,et al.  Maintenance of acetylcholine receptor number by neuregulins at the neuromuscular junction in vivo. , 1997, Science.

[22]  R. Griggs,et al.  Mode Switching Kinetics Produced by a Naturally Occurring Mutation in the Cytoplasmic Loop of the Human Acetylcholine Receptor ε Subunit , 1998, Neuron.

[23]  T. Eken Spontaneous electromyographic activity in adult rat soleus muscle. , 1998, Journal of neurophysiology.

[24]  G. Yancopoulos,et al.  Cloning and Characterization of Muscle-Specific Kinase in Chicken , 2000, Molecular and Cellular Neuroscience.

[25]  S. J. Wood,et al.  Safety factor at the neuromuscular junction , 2001, Progress in Neurobiology.

[26]  A. Vincent,et al.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies , 2001, Nature Medicine.

[27]  G. Davis,et al.  Maintaining the stability of neural function: a homeostatic hypothesis. , 2001, Annual review of physiology.

[28]  K. A. Wall,et al.  Split Tolerance in a Novel Transgenic Model of Autoimmune Myasthenia Gravis1 , 2002, The Journal of Immunology.

[29]  V. Murthy,et al.  Synaptic gain control and homeostasis , 2003, Current Opinion in Neurobiology.

[30]  P. Tonali,et al.  Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. , 2003, Brain : a journal of neurology.

[31]  A. Engel,et al.  Are MuSK antibodies the primary cause of myasthenic symptoms? , 2004, Neurology.

[32]  A. Vincent,et al.  Detection and characterization of MuSK antibodies in seronegative myasthenia gravis , 2004, Annals of neurology.

[33]  C. Legay,et al.  MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction , 2004, The Journal of cell biology.

[34]  J. Cartaud,et al.  The synaptic muscle‐specific kinase (MuSK) complex: New partners, new functions , 2005, BioEssays : news and reviews in molecular, cellular and developmental biology.

[35]  A. Vincent,et al.  Acetylcholine receptors loss and postsynaptic damage in MuSK antibody–positive myasthenia gravis , 2005, Annals of neurology.

[36]  M. Oshima,et al.  Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK) , 2006, Journal of Neuroimmunology.

[37]  L. Fradkin,et al.  Dystrophin Is Required for Appropriate Retrograde Control of Neurotransmitter Release at the Drosophila Neuromuscular Junction , 2006, The Journal of Neuroscience.

[38]  Y. Abe,et al.  Induction of myasthenia by immunization against muscle-specific kinase. , 2006, The Journal of clinical investigation.

[39]  A. Vincent,et al.  Single‐fiber electromyography in limb and facial muscles in muscle‐specific kinase antibody and acetylcholine receptor antibody myasthenia gravis , 2006, Muscle & nerve.

[40]  S. Dryer,et al.  Delayed synapsing muscles are more severely affected in an experimental model of MuSK-induced myasthenia gravis , 2006, Neuroscience.

[41]  M. Missler,et al.  α-Neurexins are required for efficient transmitter release and synaptic homeostasis at the mouse neuromuscular junction , 2006, Neuroscience.

[42]  P. Matthews,et al.  MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. , 2006, Brain : a journal of neurology.

[43]  F. Lee,et al.  Single-Cell Characterization of Retrograde Signaling by Brain-Derived Neurotrophic Factor , 2006, The Journal of Neuroscience.

[44]  R. Flink,et al.  Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody , 2006, Muscle & nerve.

[45]  G. Wolfe,et al.  Repetitive nerve stimulation of facial muscles in musk antibody–positive myasthenia gravis , 2006, Muscle & nerve.

[46]  B. A. Hesser,et al.  Synapse disassembly and formation of new synapses in postnatal muscle upon conditional inactivation of MuSK , 2006, Molecular and Cellular Neuroscience.

[47]  A. Vincent,et al.  Strong association of MuSK antibody–positive myasthenia gravis and HLA-DR14-DQ5 , 2006, Neurology.

[48]  P. Parren,et al.  Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange , 2007, Science.

[49]  D. Zillikens,et al.  The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases , 2007, Archives of Dermatological Research.

[50]  Rob C. G. van de Ven,et al.  Severely impaired neuromuscular synaptic transmission causes muscle weakness in the Cacna1a‐mutant mouse rolling Nagoya , 2007, The European journal of neuroscience.

[51]  A. Vincent,et al.  Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis. , 2007, The American journal of pathology.

[52]  K. Shigemoto,et al.  Clinical and experimental features of MuSK antibody positive MG in Japan , 2007, European journal of neurology.

[53]  S. Hubbard,et al.  Lrp4 Is a Receptor for Agrin and Forms a Complex with MuSK , 2008, Cell.

[54]  J. Linnoila,et al.  A Mammalian Homolog of Drosophila Tumorous Imaginal Discs, Tid1, Mediates Agrin Signaling at the Neuromuscular Junction , 2008, Neuron.

[55]  A. Vincent,et al.  Myasthenia Gravis Seronegative for Acetylcholine Receptor Antibodies , 2008, Annals of the New York Academy of Sciences.

[56]  L. Mei,et al.  LRP4 Serves as a Coreceptor of Agrin , 2008, Neuron.

[57]  O. Gervásio,et al.  Anti‐MuSK patient antibodies disrupt the mouse neuromuscular junction , 2008, Annals of neurology.

[58]  F. Dekker,et al.  Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1 , 2008, Journal of Neuroimmunology.

[59]  J. Verschuuren,et al.  Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. , 2008, Brain : a journal of neurology.

[60]  T. Rispens,et al.  Immunoglobulin G4: an odd antibody , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[61]  L. Schaeffer,et al.  Silencing rapsyn in vivo decreases acetylcholine receptors and augments sodium channels and secondary postsynaptic membrane folding , 2009, Neurobiology of Disease.

[62]  A. Vincent,et al.  The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates. , 2009, The American journal of pathology.

[63]  R. Baines,et al.  Chapter The Roles of the Dystrophin-Associated Glycoprotein Complex at the Synapse , 2011 .

[64]  Megan R. Carey,et al.  Activity-Dependent Regulation of Synapses by Retrograde Messengers , 2009, Neuron.

[65]  A. Kokla,et al.  Epidemiological and immunological profile of muscle‐specific kinase myasthenia gravis in Greece , 2009, European journal of neurology.

[66]  J. Verschuuren,et al.  Pre‐ and postsynaptic neuromuscular junction abnormalities in musk myasthenia , 2010, Muscle & nerve.

[67]  L. Mei,et al.  To build a synapse: signaling pathways in neuromuscular junction assembly , 2010, Development.

[68]  T. Gillingwater,et al.  Using mouse cranial muscles to investigate neuromuscular pathology in vivo , 2010, Neuromuscular Disorders.

[69]  R. Gold,et al.  Plasmapheresis for neuroinflammatory disorders , 2010 .

[70]  S. Ngo,et al.  Patient autoantibodies deplete postsynaptic muscle‐specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice , 2010, The Journal of physiology.

[71]  J. Palace,et al.  Clinical aspects of myasthenia explained , 2010, Autoimmunity.

[72]  S. Kalled,et al.  What is IgG4? A review of the biology of a unique immunoglobulin subtype , 2011, Current opinion in rheumatology.

[73]  A. Masuda,et al.  Anti-MuSK autoantibodies block binding of collagen Q to MuSK , 2011, Neurology.

[74]  Shuo Lin,et al.  Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice , 2011, Experimental Neurology.

[75]  D. Sanders,et al.  Anti‐musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts , 2011, Muscle & nerve.